1
|
Duan M, Du X, Ren G, Zhang Y, Zheng Y, Sun S, Zhang J. Obovatol inhibits the growth and aggressiveness of tongue squamous cell carcinoma through regulation of the EGF‑mediated JAK‑STAT signaling pathway. Mol Med Rep 2018; 18:1651-1659. [PMID: 29845251 DOI: 10.3892/mmr.2018.9078] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2016] [Accepted: 12/18/2017] [Indexed: 11/06/2022] Open
Abstract
Migration and invasion are the most important characteristics of human malignancies which limit cancer drug therapies in the clinic. Tongue squamous cell carcinoma (TSCC) is one of the rarest types of cancer, although it is characterized by a higher incidence, rapid growth and greater potential for metastasis compared with other oral neoplasms worldwide. Studies have demonstrated that the phenolic compound obovatol exhibits anti‑tumor effects. However, the potential mechanisms underlying obovatol‑mediated signaling pathways have not been completely elucidated in TSCC. The present study investigated the anti‑tumor effects and potential molecular mechanisms mediated by obovatol in TSCC cells and tissues. The results of the present study demonstrated that obovatol exerted cytotoxicity in SCC9 TSCC cells, and inhibited their migration and invasion. In addition, obovatol induced apoptosis in SCC9 TSCC cells by increasing caspase 9/3 and apoptotic protease enhancing factor 1 expression levels. Western blot analysis demonstrated that obovatol inhibited the expression of pro‑epidermal growth factor (EGF), Janus kinase (JAK), and signal transducer and activator of transcription (STAT) in SCC9 TSCC cells. A study of the molecular mechanisms demonstrated that depletion of EGF reversed the obovatol‑mediated inhibition of SCC9 TSCC cell growth and aggressiveness. Animal experiments indicated that obovatol significantly inhibited TSCC tumor growth and increased the number of apoptotic cells in tumor tissues. In conclusion, the results of the present study provided scientific evidence that obovatol inhibited TSCC cell growth and aggressiveness through the EGF‑mediated JAK‑STAT signaling pathway, suggesting that obovatol may be a potential anti‑TSCC agent.
Collapse
Affiliation(s)
- Mingli Duan
- Department of Stomatology, Tianjin First Center Hospital Dental, Tianjin, Hebei 300192, P.R. China
| | - Xiaoming Du
- Department of Maxillofacial Surgery, Tianjin Stomatological Hospital and Maxillofacial Surgery, Tianjin, Hebei 300041, P.R. China
| | - Gang Ren
- Department of Stomatology, Tianjin First Center Hospital Dental, Tianjin, Hebei 300192, P.R. China
| | - Yongdong Zhang
- Department of Stomatology, Tianjin First Center Hospital Dental, Tianjin, Hebei 300192, P.R. China
| | - Yu Zheng
- Department of Stomatology, Tianjin First Center Hospital Dental, Tianjin, Hebei 300192, P.R. China
| | - Shuping Sun
- Department of Maxillofacial Surgery, Tianjin Stomatological Hospital and Maxillofacial Surgery, Tianjin, Hebei 300041, P.R. China
| | - Jun Zhang
- Department of Maxillofacial Surgery, Tianjin Stomatological Hospital and Maxillofacial Surgery, Tianjin, Hebei 300041, P.R. China
| |
Collapse
|
4
|
Chen C, Kane M, Song J, Campana J, Raben A, Hu K, Harrison L, Quon H, Dancey J, Baron A, Said S, Eckhardt SG, Raben D. Phase I Trial of Gefitinib in Combination With Radiation or Chemoradiation for Patients With Locally Advanced Squamous Cell Head and Neck Cancer. J Clin Oncol 2007; 25:4880-6. [DOI: 10.1200/jco.2007.12.9650] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PurposeTo establish the safety and toxicity profile of daily gefitinib with radiation alone or with concurrent chemoradiotherapy in previously untreated patients with locally advanced squamous cell head and neck cancer (LAHNC).Patients and MethodsPatients with intermediate-stage LAHNC were treated with concomitant boost radiation (RT) alone with escalating doses of daily gefitinib (250 or 500 mg; cohort I). Once a safety profile was determined with RT alone, patients with high-risk disease were then treated with daily gefitinib (250 or 500 mg), weekly cisplatin (CDDP; 30 mg/m2), and once-daily RT (cohort II). Patients also received post-RT gefitinib at 250 mg daily for a period of up to 2 years.ResultsTwenty-three patients were enrolled and assessable for toxicity. No dose-limiting toxicities (DLTs) were observed in patients treated in cohort I at either 250 or 500 mg of gefitinib daily with concomitant boost RT to 72 Gy. In patients receiving chemoradiotherapy and gefitinib (cohort II), DLTs included one grade 4 diarrhea and one grade 4 neutropenic fever. Fifteen patients started maintenance gefitinib, and eight (53%) experienced grade 1 to 2 acne-like skin rash and diarrhea, but no grade 3 or 4 toxicity occurred.ConclusionGefitinib (250 or 500 mg daily) was well tolerated with concomitant boost RT or concurrent chemoradiotherapy with weekly CDDP. Protracted administration of gefitinib for up to 2 years at 250 mg daily was also tolerated well.
Collapse
Affiliation(s)
- Changhu Chen
- From the Departments of Radiation Oncology, Medical Oncology, Otolaryngology, Preventive Medicine and Biometrics, and Pathology, University of Colorado, Aurora, CO; Department of Radiation Oncology, Christiana Hospital Medical Center, Wilmington, DE; Department of Radiation Oncology, Beth Israel Medical Center, New York, NY; Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA; and National Cancer Institute, Bethesda, MD
| | - Madeleine Kane
- From the Departments of Radiation Oncology, Medical Oncology, Otolaryngology, Preventive Medicine and Biometrics, and Pathology, University of Colorado, Aurora, CO; Department of Radiation Oncology, Christiana Hospital Medical Center, Wilmington, DE; Department of Radiation Oncology, Beth Israel Medical Center, New York, NY; Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA; and National Cancer Institute, Bethesda, MD
| | - John Song
- From the Departments of Radiation Oncology, Medical Oncology, Otolaryngology, Preventive Medicine and Biometrics, and Pathology, University of Colorado, Aurora, CO; Department of Radiation Oncology, Christiana Hospital Medical Center, Wilmington, DE; Department of Radiation Oncology, Beth Israel Medical Center, New York, NY; Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA; and National Cancer Institute, Bethesda, MD
| | - John Campana
- From the Departments of Radiation Oncology, Medical Oncology, Otolaryngology, Preventive Medicine and Biometrics, and Pathology, University of Colorado, Aurora, CO; Department of Radiation Oncology, Christiana Hospital Medical Center, Wilmington, DE; Department of Radiation Oncology, Beth Israel Medical Center, New York, NY; Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA; and National Cancer Institute, Bethesda, MD
| | - Adam Raben
- From the Departments of Radiation Oncology, Medical Oncology, Otolaryngology, Preventive Medicine and Biometrics, and Pathology, University of Colorado, Aurora, CO; Department of Radiation Oncology, Christiana Hospital Medical Center, Wilmington, DE; Department of Radiation Oncology, Beth Israel Medical Center, New York, NY; Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA; and National Cancer Institute, Bethesda, MD
| | - Kenneth Hu
- From the Departments of Radiation Oncology, Medical Oncology, Otolaryngology, Preventive Medicine and Biometrics, and Pathology, University of Colorado, Aurora, CO; Department of Radiation Oncology, Christiana Hospital Medical Center, Wilmington, DE; Department of Radiation Oncology, Beth Israel Medical Center, New York, NY; Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA; and National Cancer Institute, Bethesda, MD
| | - Louis Harrison
- From the Departments of Radiation Oncology, Medical Oncology, Otolaryngology, Preventive Medicine and Biometrics, and Pathology, University of Colorado, Aurora, CO; Department of Radiation Oncology, Christiana Hospital Medical Center, Wilmington, DE; Department of Radiation Oncology, Beth Israel Medical Center, New York, NY; Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA; and National Cancer Institute, Bethesda, MD
| | - Harry Quon
- From the Departments of Radiation Oncology, Medical Oncology, Otolaryngology, Preventive Medicine and Biometrics, and Pathology, University of Colorado, Aurora, CO; Department of Radiation Oncology, Christiana Hospital Medical Center, Wilmington, DE; Department of Radiation Oncology, Beth Israel Medical Center, New York, NY; Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA; and National Cancer Institute, Bethesda, MD
| | - Janet Dancey
- From the Departments of Radiation Oncology, Medical Oncology, Otolaryngology, Preventive Medicine and Biometrics, and Pathology, University of Colorado, Aurora, CO; Department of Radiation Oncology, Christiana Hospital Medical Center, Wilmington, DE; Department of Radiation Oncology, Beth Israel Medical Center, New York, NY; Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA; and National Cancer Institute, Bethesda, MD
| | - Anna Baron
- From the Departments of Radiation Oncology, Medical Oncology, Otolaryngology, Preventive Medicine and Biometrics, and Pathology, University of Colorado, Aurora, CO; Department of Radiation Oncology, Christiana Hospital Medical Center, Wilmington, DE; Department of Radiation Oncology, Beth Israel Medical Center, New York, NY; Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA; and National Cancer Institute, Bethesda, MD
| | - Sherif Said
- From the Departments of Radiation Oncology, Medical Oncology, Otolaryngology, Preventive Medicine and Biometrics, and Pathology, University of Colorado, Aurora, CO; Department of Radiation Oncology, Christiana Hospital Medical Center, Wilmington, DE; Department of Radiation Oncology, Beth Israel Medical Center, New York, NY; Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA; and National Cancer Institute, Bethesda, MD
| | - S. Gail Eckhardt
- From the Departments of Radiation Oncology, Medical Oncology, Otolaryngology, Preventive Medicine and Biometrics, and Pathology, University of Colorado, Aurora, CO; Department of Radiation Oncology, Christiana Hospital Medical Center, Wilmington, DE; Department of Radiation Oncology, Beth Israel Medical Center, New York, NY; Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA; and National Cancer Institute, Bethesda, MD
| | - David Raben
- From the Departments of Radiation Oncology, Medical Oncology, Otolaryngology, Preventive Medicine and Biometrics, and Pathology, University of Colorado, Aurora, CO; Department of Radiation Oncology, Christiana Hospital Medical Center, Wilmington, DE; Department of Radiation Oncology, Beth Israel Medical Center, New York, NY; Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA; and National Cancer Institute, Bethesda, MD
| |
Collapse
|